A UMass Medical School pharmacy expert is warning managed care plans to keep close tabs on an array of innovative – but also very expensive – gene therapies, according to Managed Healthcare Executive and Specialty Pharmacy Continuum.
A UMass Medical School clinical pharmacist will present on which specialty drugs are poised to be approved by the U.S. Food and Drug Administration in 2018 and how they will impact health plan budgets at AMCP Nexus 2017.
InterveneRx is launching its InterV CM+ platform with Allied National, Inc. in a first of its kind care management program for specialty drug patients that integrates evidenced based protocols with biometric devices and a mobile application for real-time clinical monitoring. Over 50 patients across 19 states will be monitored for improvements in clinical outcomes, utilization and patient engagement. UMass Medical School is providing a clinically enhanced specialty drug prior authorization process.
A first of its kind pilot that will in January begin monitoring patients on specialty drugs in real-time is a partnership between UMass Medical School and tech startup InterVRX, according to an article in Specialty Pharmacy Continuum.
A pharmacist from UMass Medical School’s Clinical Pharmacy Services discusses the efficacy and expected costs of specialty drugs in the pipeline for nonalcoholic steatohepatitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and ovarian cancer in Specialty Pharmacy Continuum.
UMass Medical School’s Clinical Pharmacy Services has partnered with InterVRx to review the accuracy, completeness and usability of specialty drug clinical protocols used within its patient monitoring platform.
A clinical pharmacist from UMass Medical School’s Clinical Pharmacy Services division will present on high-impact specialty pipeline drugs expected to reach the market, with a focus on their budget impact, at the Eastern Medicaid Pharmacy Administrators Association’s 40th annual meeting Nov. 14 at Wentworth by the Sea in New Castle, N.H.
A clinical pharmacist from UMass Medical School’s Clinical Pharmacy Services division will present on promising specialty medications with the biggest impact on drug spend expected to receive approval from the U.S. Food and Drug Administration (FDA) within the next two years at the Academy of Managed Care Pharmacy’s Nexus 2016 conference, being held Oct. 3-6 in National Harbor, Maryland.
Armada Health Care has partnered with UMass Medical School’s Clinical Pharmacy Services to provide enhancements and support regarding clinical protocols and therapy interventions within the ArmadaOne Specialty Pharmacy Workflow Platform.